论文部分内容阅读
目的探讨聚乙二醇a-2b干扰素(PEG-IFNa-2b)治疗丙型肝炎的临床疗效。方法选取徐州市传染病医院2014年9月—2016年7月收治的丙型肝炎患者120例,随机分为PEG-IFNa-2b组和干扰素a-2b(IFNa-2b)组,每组60例。PEG-IFNa-2b组患者给予PEG-IFNa-2b联合利巴韦林治疗,IFNa-2b组患者给予IFNa-2b联合利巴韦林治疗,两组患者均持续治疗48周。比较两组患者抗病毒治疗效果与高、低病毒载量获得率。结果PEG-IFNa-2b组患者快速病毒学应答(RVR)、早期病毒学应答(EVR)及持续病毒学应答(SVR)获得率高于IFNa-2b组(P<0.05)。在高病毒载量上,PEG-IFNa-2b组患者EVR、SVR、RVR获得率高于IFNa-2b组(P<0.05)。两组患者低病毒载量获得率比较,差异无统计学意义(P>0.05)。结论 PEG-IFNa-2b治疗丙型肝炎的临床疗效确切,尤其在高病毒载量患者中借鉴意义更大。
Objective To investigate the clinical efficacy of pegylated interferon alfa-2b (IFN-2b) in the treatment of hepatitis C patients. Methods A total of 120 patients with hepatitis C who were admitted to Xuzhou Infectious Disease Hospital from September 2014 to July 2016 were randomly divided into PEG-IFNa-2b group and interferon-2b (IFNa-2b) group example. Patients in the PEG-IFNa-2b group received PEG-IFNa-2b plus ribavirin, IFNa-2b patients received IFNa-2b plus ribavirin, and both patients were treated for 48 weeks. Antiviral treatment efficacy and high and low viral load gain rates were compared between the two groups. Results The rates of rapid virological response (RVR), early virological response (EVR) and sustained virological response (SVR) in PEG-IFNa-2b group were higher than those in IFNa-2b group (P <0.05). In high viral load, the acquisition rate of EVR, SVR and RVR in PEG-IFNa-2b group was higher than that in IFNa-2b group (P <0.05). There was no significant difference between the two groups in the acquisition rate of low viral load (P> 0.05). Conclusion The clinical efficacy of PEG-IFNa-2b in the treatment of hepatitis C is exact, especially in high viral load patients.